Insulin-like peptide 5 fails to improve metabolism or body weight in obese mice.

Peptides 2019 Jul 23;120:170116. Epub 2019 Jul 23.

Novo Nordisk Research Center, Indianapolis, IN, 46241, USA.

Insulin-like peptide 5 (INSL5) is a member of the insulin-like family of peptides. It has been reported to be orexigenic in rodent models of obesity with impaired glucose metabolism. We attempted to confirm this property as a first step in establishing the ability of INSL5 to successfully integrate with other agents more proven in their ability to reverse obesity and improve metabolism. INSL5 was chemically synthesized by two alternative methods to a native form and one that was site-specifically conjugated to a 20 KDa polyethylene glycol (PEG) polymer. The pharmacology of each peptide was assessed by high-dose chronic administration in normal and obese mice. INSL5 failed to produce pharmacologically relevant effects on food intake, body weight or glucose control indicative of a negligible role of the peptide in the control of feeding and glucose metabolism.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.peptides.2019.170116DOI Listing
July 2019

Publication Analysis

Top Keywords

body weight
8
obese mice
8
glucose metabolism
8
improve metabolism
8
insulin-like peptide
8
polymer pharmacology
4
native form
4
alternative methods
4
form site-specifically
4
methods native
4
site-specifically conjugated
4
polyethylene glycol
4
20 kda polyethylene
4
peg polymer
4
conjugated 20 kda
4
glycol peg
4
chemically synthesized
4
agents proven
4
integrate agents
4
insl5 integrate
4

Similar Publications